- Five-yea esea ch p oject u ites 42 public a d p ivate pa t e s ac oss 17 cou t ies to co duct 22 cli ical studies i volvi g 14,000+ patie ts; fi st patie ts will be e olled this mo th
- P oject aims to help ca diac patie ts avoid dete io atio th ough ea ly, pe so alized i te ve tio s delive ed ac oss the ca diac ca e jou ey
- I te ve tio s will be co-c eated with patie ts a d desig ed to systematically add ess socioeco omic, sex- a d ge de – elated a d digital access gaps
- With a total budget of EUR 27.6 millio , the p oject is co-fu ded by the Eu opea U io I ovative Health I itiative (IHI) a d i dust y pa t e s
- Ci cle CVI b i gs expe tise i AI-e abled ca diovascula MR a d CT image a alysis, suppo ti g the co so tium’s focus o ea lie diag osis, pe so alized isk assessme t a d imagi g-guided ca e.
CALGARY, Albe ta, Oct. 20, 2026 (GLOBE NEWSWIRE) — Ci cle Ca diovascula Imagi g (Ci cle CVI), a p ovide of AI-e abled ca diovascula imagi g softwa e, today a ou ced its pa ticipatio i EXIT-CVD, a five-yea esea ch p oject b i gi g togethe 42 public a d p ivate pa t e s ac oss 17 cou t ies. Co-fu ded by the Eu opea U io ’s I ovative Health I itiative (IHI) a d i dust y pa t e s, the co so tium is led by U ive sity Medical Ce te G o i ge (UMCG) a d Philips a d aims to t a sfo m how ca diovascula disease is detected, mo ito ed a d t eated. The p oject will co duct 22 cli ical studies i volvi g mo e tha 14,000 patie ts, i vestigati g oppo tu ities to p eve t disease befo e it develops, eve se disease p og essio o halt dete io atio i adva ced disease. Patie t e ollme t fo the fi st studies is scheduled to begi i Octobe 2026.
Ca diovascula health is fu dame tal to ove all health a d well-bei g, yet mo e tha 60 millio people i the Eu opea U io a e livi g with ca diovascula disease. Fo ma y, the co ditio sig ifica tly educes quality of life a d well-bei g. Without ea ly detectio , timely diag osis a d app op iate t eatme t, ca diovascula disease ca p og ess sile tly f om ea ly isk facto s to established disease a d ultimately, ca diac eve ts that may lead to p ematu e death.
“Ou visio is a futu e whe e hea t disease is o lo ge a i eve sible pathway,” said P ofesso Pim va de Ha st, P oject Coo di ato of EXIT-CVD a d Head of Ca diology at the U ive sity Medical Ce te G o i ge . “By u de sta di g both the biological a d social d ive s of ca diovascula disease, a d deployi g i teg ated i ovatio s ac oss diag ostics, mo ito i g, a d ca e, we ca empowe patie ts a d cli icia s to exit the disease co ti uum befo e it’s too late.”
“Fo mo e tha 30 yea s, we have viewed ca diovascula disease as a co ti uous jou ey, f om isk facto s such as hype te sio , to athe oscle osis, a fi st ca diac eve t a d ultimately, fo ma y patie ts, hea t failu e,” said Robi Nijveldt, Chief of Ca diology at UMC Ut echt. “Yet most of us imp ove ca e withi ou ow specialty a d a ely have a complete view of the patie t’s expe ie ce. EXIT-CVD is a ambitious effo t to build that holistic view togethe , helpi g t a sfo m ca diac ca e fo millio s of patie ts ac oss Eu ope.”
The EXIT-CVD cli ical studies will focus o the th ee key exit poi ts alo g the ca diac ca e jou ey: ea ly detectio th ough digital mo ito i g (ea ly exit), pe so alized isk assessme t a d ta geted i te ve tio s (mid exit), a d adva ced the apies to suppo t ecove y i late -stage disease (late exit). By combi i g diag ostics, digital tools a d adva ced the apeutic app oaches, EXIT-CVD aims to delive actio able, evide ce-based st ategies that ca be impleme ted ac oss dive se healthca e systems i Eu ope.
“Adva ced ca diovascula imagi g ca help cli icia s u de sta d ot o ly what disease looks like today, but how it may p og ess a d whe e i te ve tio could make a diffe e ce,” said E ka Akyuz, CEO at Ci cle Ca diovascula Imagi g. “EXIT-CVD b i gs togethe the cli ical, tech ology a d patie t pe spectives eeded to explo e those oppo tu ities ac oss the ca e jou ey. We a e p oud to joi this collabo atio a d b i g ou expe tise i AI-e abled image a alysis to its ambitio of ea lie , mo e pe so alized ca diovascula ca e.”
Ci cle CVI b i gs expe tise i AI-e abled ca diovascula image a alysis th ough its cvi42 platfo m, which combi es ca diac MR a d CT a alysis, co o a y plaque qua tificatio , a d tools fo st uctu al hea t a d elect ophysiology p ocedu e pla i g withi a u ified e vi o me t. Its capabilities i clude assessme t of ca diac fu ctio , blood flow, myoca dial tissue cha acte istics a d co o a y a te y disease, helpi g cli icia s t a slate complex imagi g data i to qua titative fi di gs. This expe tise alig s EXIT-CVD’s emphasis o imagi g-guided disease st atificatio a d pe so alized cli ical decisio -maki g.
- Came a-Based I -Hospital Mo ito i g (
CARDIO-CAM study): Deployme t a d evaluatio of a u obt usive, video-based patie t mo ito i g system that co ti uously captu es ca dio espi ato y sig als a d eleva t cli ical co text. - Spect al CT fo Ea ly Detectio , Risk St atificatio a d Pe so alized Patie t Ca e Pathways (
LEADER-PAD study): Developme t a d validatio of ew app oaches fo the ea ly detectio of ca diovascula disease i asymptomatic a d low isk symptomatic patie ts usi g spect al CT. - Nu se/HCP-Led Remote Hea t Failu e Mo ito i g (
REMODEL-HF study): Multi atio al a domized study evaluati g the Hea t Failu e Ma ageme t System (HFMS), a o -i vasive emote mo ito i g tech ology, i patie ts ece tly hospitalized fo hea t failu e, with the objective of imp ovi g outcomes a d optimizi g guideli e-di ected medical the apy. - Imagi g-Guided PCI Ra domized T ial (
GUIDANCE-PCCT study): Evaluatio of cli ical a d p ocedu al outcomes of PCI guided by photo cou ti g CT ve sus sta da d a giog aphy-guided PCI. - Adva ced Imagi g i I filt ative Ca diomyopathies (
NOTIFY-2 study): Validatio of AI-d ive image a d ECG a alysis algo ithms to imp ove ea ly diag osis of Left Ve t icula Hype t ophy (LVH) a d u de lyi g disease isk st atificatio .
Cli ical a d academic pa t e s: Hospital de la Sa ta C eu i Sa t Pau (Spai ), Politec ico di Mila o (Italy), U ive sity of Pavia (Italy), Ce t o Ca diologico Mo zi o (Italy), EOC (Switze la d), KU Leuve (Belgium), NIKARD (Pola d), UMC Ut echt (Nethe la ds), UMC G o i ge (Nethe la ds), Tech ical U ive sity Ei dhove (Nethe la ds), U ive sitätskli ikum Köl (Ge ma y), Ki g’s College Lo do (UK), Lo do School of Eco omics a d Political Scie ce (UK), a d Va si ais-Suome Hyvi voi tialue (Fi la d).I dust y pa t e s: Philips, Ci cle CVI, GE Healthca e, Sieme s Healthi ee s, Hea tBeam, Medt o ic, Huawei, XVIVO Pe fusio , Ast aZe eca, Ca diomed, Megi Health, Viat is, Co dys, Nova tis, Co botics, ZOLL, Sa ofi, Repai o , Joh so & Joh so MedTech Hea t Recove y, O se tia, a d CogStackHealthca e co sulta cy: B idg Ou a d IQVIA Solutio sPatie t o ga izatio : Stichti g V ouwe Ha tMedical associatio : Eu opea Society of Ca diology (ESC)
Mo e i fo matio ca be viewed o the EXIT-CVD website.
This p oject is suppo ted by the I ovative Health I itiative Joi t U de taki g (IHI JU) u de g a t ag eeme t No 101253160. The JU eceives suppo t f om the Eu opea U io ‘s Ho izo Eu ope esea ch a d i ovatio p og am a d COCIR, EFPIA, Eu opa Bío, MedTech Eu ope, a d Vacci es Eu ope. Fu ded by the Eu opea U io , the p ivate membe s, a d those co t ibuti g pa t e s of the IHI JU. Views a d opi io s exp essed a e those of the autho (s) o ly a d do ot ecessa ily eflect those of the afo eme tio ed pa ties. Neithe of the afo eme tio ed pa ties ca be held espo sible fo them.
ma keti g@ci clecvi.com
Ci cle Ca diovascula Imagi g (Ci cle CVI) develops AI-e abled softwa e fo ca diovascula image a alysis, visualizatio a d epo ti g. Its flagship platfo m, cvi42, b i gs togethe ca diac MR, ca diac CT, vascula CT, st uctu al hea t pla i g a d elect ophysiology pla i g tools i a u ified, ve do – eut al e vi o me t. Desig ed fo cli ical a d esea ch wo kflows, Ci cle’s solutio s combi e automated a alysis, qua titative assessme t a d i teg ated epo ti g to suppo t efficie t, ep oducible ca diovascula imagi g. Fo mo e i fo matio , visit www.ci clecvi.com.
